247186-56-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 3-formylbenzoate is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of various medicinal compounds.
Used in Food Industry:
Tert-Butyl 3-formylbenzoate is used as a flavoring agent for its fruity odor, enhancing the taste and aroma of food products.
Used in Perfume Industry:
Tert-Butyl 3-formylbenzoate is used in the production of perfumes, capitalizing on its fruity scent to create appealing fragrances.
Used in Cosmetic Industry:
Tert-Butyl 3-formylbenzoate is incorporated as a component in cosmetic products, utilizing its properties to contribute to the formulation of various beauty and personal care items.
Safety Precautions:
It is important to handle Tert-Butyl 3-formylbenzoate with care, as it can cause irritation to the skin, eyes, and respiratory system if not properly managed.

Upstream product

• 71432-55-8 2-tert-butyl-1,3-diisopropylisourea 
• 619-21-6 m-formylphenyl benzoic acid 
• 1877-71-0 benzene 1,3-dicarboxylic acid monomethyl ester 
• 75-65-0 tert-butyl alcohol 
• 67853-03-6 methyl 3-(hydroxymethyl)benzoate 
• 69038-74-0 tert-butyl 3-bromobenzoate 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 215522-96-6 3-hydroxymethyl-benzoic acid tert-butyl ester 
• 945222-47-9 C₁₄H₂₀O₃ 
• 889856-38-6 tert-butyl 3-[(1S)-1-hydroxypropyl]benzoate 
• 1427753-48-7 tert-butyl 3-[(1E)-3-(benzyloxy)-3-oxopropa-1-en-1-yl]benzoate 

Relevant academic research and scientific papers

Bisubstrate inhibitors of nicotinamide N-methyltransferase (NNMT) with enhanced activity

Nicotinamide N-methyltransferase (NNMT) catalyzes the methylation of nicotinamide to form N-methylnicotinamide. Overexpression of NNMT is associated with a variety of diseases, including a number of cancers and metabolic disorders, suggesting a role for NNMT as a potential therapeutic target. By structural modification of a lead NNMT inhibitor previously developed in our group, we prepared a diverse library of inhibitors to probe the different regions of the enzyme's active site. This investigation revealed that incorporation of a naphthalene moiety, intended to bind the hydrophobic nicotinamide binding pocket via π-πstacking interactions, significantly increases the activity of bisubstrate-like NNMT inhibitors (half-maximal inhibitory concentration 1.41 μM). These findings are further supported by isothermal titration calorimetry binding assays as well as modeling studies. The most active NNMT inhibitor identified in the present study demonstrated a dose-dependent inhibitory effect on the cell proliferation of the HSC-2 human oral cancer cell line.

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein ring A, X1, X2, X3, R2, R4b, R10, and G have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention, and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

Development of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as orally active human chymase inhibitors

A novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones was designed, synthesized, and evaluated as human chymase inhibitors. From this series, we identified several compounds which were effective, via oral administration, in a mou

Ring formylation of bromobenzoate esters by direct metalation

A study on the synthesis of a benzaldehyde containing an ester function directly from tert-butyl 4-lithiobenzate was described, t-Butyl 4- bromobenzoate reacted with butyllithium at -78°C in THF, followed by immediate addition of DMF to give the desired benzaldehyde in moderate yield. The scope of this reaction was examined.